DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ. et al
Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Lancet 2013;
382 (9897) 1021-1028
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.